期刊
LANCET
卷 388, 期 10043, 页码 505-517出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(15)01124-1
关键词
-
资金
- Merck
- GE Healthcare
- Piramal
- Alzheimer Nederland
- Dioraphte
- Stichting VUmc Fonds
- Stichting Alzheimer & Neuropsychiatrie
- Fujirebio Europe
- Lundbeck
- Janssen
- NIA ADNI
- DIAN
- A4
- Alz Assoc DIAN
- Lilly
- Biogen
- Genentech
- Bayer
- Avid
- Roche
- Functional Neuromodulation
- ZonMW
- NWO
- EU-FP7
- CardioVascular Onderzoek Nederland
- Stichting Dioraphte
- Gieskes-Strijbis fonds
- Boehringer Ingelheim
- Piramal Neuroimaging
- Janssen Stellar
Although the prevalence of dementia continues to increase worldwide, incidence in the western world might have decreased as a result of better vascular care and improved brain health. Alzheimer's disease, the most prevalent cause of dementia, is still defined by the combined presence of amyloid and tau, but researchers are gradually moving away from the simple assumption of linear causality as proposed in the original amyloid hypothesis. Age-related, protective, and disease-promoting factors probably interact with the core mechanisms of the disease. Amyloid beta 42, and tau proteins are established core cerebrospinal biomarkers; novel candidate biomarkers include amyloid beta oligomers and synaptic markers. MRI and fluorodeoxyglucose PET are established imaging techniques for diagnosis of Alzheimer's disease. Amyloid PET is gaining traction in the clinical arena, but validity and cost-effectiveness remain to be established. Tau PET might off er new insights and be of great help in differential diagnosis and selection of patients for trials. In the search for understanding the disease mechanism and keys to treatment, research is moving increasingly into the earliest phase of disease. Preclinical Alzheimer's disease is defined as biomarker evidence of Alzheimer's pathological changes in cognitively healthy individuals. Patients with subjective cognitive decline have been identified as a useful population in whom to look for preclinical Alzheimer's disease. Moderately positive results for interventions targeting several lifestyle factors in non-demented elderly patients and moderately positive interim results for lowering amyloid in pre-dementia Alzheimer's disease suggest that, ultimately, there will be a future in which specific anti-Alzheimer's therapy will be combined with lifestyle interventions targeting general brain health to jointly combat the disease. In this Seminar, we discuss the main developments in Alzheimer's research.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据